The liver harbors a distinct capacity for endogenous regeneration; however, liver regeneration is often impaired in disease and therefore insufficient to compensate for the loss of hepatocytes and organ function. Here we describe a functional genetic approach for the identification of gene targets that can be exploited to increase the regenerative capacity of hepatocytes. Pools of small hairpin RNAs (shRNAs) were directly and stably delivered into mouse livers to screen for genes modulating liver regeneration. Our studies identify the dual-specific kinase MKK4 as a master regulator of liver regeneration. MKK4 silencing robustly increased the regenerative capacity of hepatocytes in mouse models of liver regeneration and acute and chronic liver failure. Mechanistically, induction of MKK7 and a JNK1-dependent activation of the AP1 transcription factor ATF2 and the Ets factor ELK1 are crucial for increased regeneration of hepatocytes with MKK4 silencing.
INTRODUCTION
Impaired organ functionality due to aging or disease represents a major cause of death in humans. Various metazoa such as planarian or axolotl (Sá nchez Alvarado and Tsonis, 2006; McCusker and Gardiner, 2011) harbor the capacity for endogenous tissue regeneration upon loss of whole parts of the body. Endogenous regeneration in metazoans occurs either via locally differentiating, but nondividing, stem cells (morphallaxis) or via dedifferentiation and expansion of differentiated cells at the site of damage or loss of tissue (epimorphosis) (Poss et al., 2003) . In contrast to lower metazoa species, the ability for endogenous tissue regeneration is limited in mammals, with one prominent exception, the liver. The liver harbors an enormous regenerative capacity, whereas in mice full liver mass and function can be restored within less than 2 weeks of surgical removal of up to two-thirds of the liver or after toxic liver damage. Liver regeneration can be seen as an example for epimorphosis, since differentiated hepatocytes residing in the G 0 phase of the cell cycle re-enter the cell cycle to give rise to new hepatocytes (Michalopoulos, 2007) .
Despite its distinct intrinsic capacity for endogenous regeneration, there are various disease conditions where this capacity is not sufficient to compensate for the loss of hepatocytes and organ function. In humans and rodents, at least 10%-15% intact liver mass is needed to maintain the liver's homeostatic functions and for recovery from liver damage (Gaub and Iversen, 1984; Starzl et al., 1975) . Any acute or chronic liver damage leading to a more profound liver damage ultimately results in fatal acute or chronic liver failure. While acute liver failure is relatively rare, chronic liver failure with associated development of liver fibrosis, and finally cirrhosis, is associated with one million deaths each year (World Health Organization, 2011) . Persistent viral infections with hepatitis B (HBV) (Lok and McMahon, 2009) or C virus (HCV) (Shepard et al., 2005) are the major causes for chronic liver damage and liver cirrhosis. However, the number of patients suffering from chronic liver damage due to alcohol abuse or from nonalcoholic fatty liver disease (NAFLD), as a result of malnutrition or metabolic disease such as diabetes, is steadily increasing.
Despite the fact that hepatocytes harbor a nearly infinite capacity to proliferate in vivo, as shown by serial transplantation experiments (Overturf et al., 1997a) , regeneration defects encountered in liver diseases make liver transplantation the only definitive treatment option for fulminant acute liver failure and end-stage chronic liver disease. The number of donors, however, is limited and new strategies to increase the regenerative capacity of damaged livers are urgently needed.
We aimed to functionally identify gene targets that can be exploited to increase the regenerative capacity of hepatocytes. By screening pools of small hairpin RNAs (shRNAs) directly in mouse livers in vivo, we identified the dual-specific kinase MKK4 as a master regulator of liver regeneration. MKK4 suppression significantly increased the regenerative capacity of hepatocytes in mouse models of liver repopulation and regeneration and showed marked therapeutic efficacy in disease models of acute and chronic liver failure. Strikingly, MKK4 suppression in hepatocytes reduced fibrosis after chronic liver damage. Hepatocytes with stable RNA interference (RNAi)-mediated MKK4 silencing show faster cell-cycle entry and progression during liver regeneration, dependent on an upregulation of MKK7 and JNK1-mediated activation of the AP1 transcription factor ATF2 and the Ets factor ELK1. Our study identifies and validates MKK4 as a therapeutic target to increase hepatocyte regeneration and provides one blueprint for functionally identifying gene targets to increase the endogenous regenerative capacity of tissues.
RESULTS

Stable Repopulation of Mouse Livers with shRNA-Encoding Transposable Elements
The fumarylacetoacetate hydrolase (FAH) knockout mouse is a well-established system, wherein FAH À/À livers can be selectively repopulated from FAH-expressing hepatocytes (Overturf et al., 1996) . The lethality of mice deficient for FAH, an enzyme involved in tyrosine catabolism, is prevented by continuous treatment with the drug nitisinone (NTBC), which blocks the accumulation of intermediary hepatotoxins ( Figure S1 ) (Grompe et al., 1995) . FAH À/À mice undergo liver failure and die shortly after NTBC withdrawal. In livers of untreated FAH À/À mice, there is a strong selection pressure for FAH-expressing hepatocytes that can be used to repopulate these livers from transplanted hepatocytes with profound FAH expression or from hepatocytes after retroviral correction of the FAH gene defect (Overturf et al., 1996) . We generated transposable elements for stable coexpression of FAH, green fluorescent protein (GFP) and microRNA-based shRNAs (shRNAmir, hereafter referred to as shRNAs) (Chang et al., 2006) that allow for an efficient suppression of target gene expression ( Figures 1A and 1B) . To test whether FAH À/À mouse livers could be repopulated from FAH-expressing hepatocytes with stable shRNA expression, we used hydrodynamic injection (Hickman et al., 1994) to stably deliver transposable elements coexpressing FAH and a nontargeting shRNA (shNC) together with sleeping beauty transposase (SB13) (Zayed et al., 2004) into hepatocytes of FAH À/À livers ( Figure S2A ). It has been shown that effective liver repopulation in FAH À/À mice is accompanied by an increase of body weight over time (Overturf et al., 1997b) and we therefore followed up body weight development of mice after stable intrahepatic delivery of transposable elements. NTBC was withdrawn 1 day after transposon delivery. Whereas all mice that had only received the FAH transposon vector without transposase (only transient, short time FAH expression in hepatocytes) died within 30 days after intrahepatic delivery ( Figure S2B ), mice that had received transposable element plus transposase showed a continuous gain of weight, regardless of GFP or shRNA coexpression ( Figure 1C ). In line with these results, efficient liver replacement from FAH/GFP/ shRNA-expressing hepatocytes was also detected by GFP imaging ( Figure 1D , left panel) on explanted mouse livers or by a-FAH immunofluorescence stainings on tissue sections from such livers ( Figure 1D , right panel). Furthermore, western blot analyses of protein lysates from repopulated mouse livers showed FAH protein levels comparable to C57/Bl6 wild-type livers ( Figure 1E ), indicating an efficient expression from the transposon vector after stable integration into the hepatocyte genome. Taken together, these data show that FAH À/À mouse livers can be efficiently repopulated from hepatocytes with stable transposon-mediated FAH and shRNA expression. To test whether stable shRNA expression results in a sufficient knockdown of target genes in hepatocytes in vivo, we hydrodynamically delivered a luciferase expression vector into mouse livers that had been stably repopulated with an shRNA targeting luciferase (shLuc) or a nontargeting shRNA (shNC). External bioluminescence imaging revealed effective suppression of luciferase activity in shLuc but not in shNC-expressing livers ( Figure 1F ). It has recently been reported that intrahepatic expression of stem-loop-stem shRNAs (25-, 23-, 21-mers) delivered by adeno-associated viruses (AAV) can result in liver toxicity (Grimm et al., 2006) ; in line with these data, unpublished data from our group showed that stable transposon-mediated intrahepatic delivery of 19-mer stem-loop-stem shRNAs (driven by the U6 promoter) can induce liver toxicity (T.W. and L.Z., unpublished data). In strong contrast, our results thus far showed efficient liver repopulation from hepatocytes stably expressing micro-RNA-based shRNAs ( Figures 1C and 1D ), without any signs of liver damage. In support of this observation, histopathological evaluation and TUNEL staining of mouse livers after stable repopulation with noncoding shRNAs did not reveal any signs of liver damage ( Figure 1G ) and serum levels of liver transaminase AST were not found elevated ( Figure 1H ), thus confirming that microRNA-based shRNAs are physiological silencing triggers that do not result in liver toxicity. Together, our data show that FAH À/À mouse livers can be efficiently and safely repopulated from hepatocytes stably expressing FAH, GFP, and shRNAs from transposable elements.
Direct In Vivo RNAi Screening for Genes that Impact the Endogenous Regenerative Capacity of Hepatocytes
We reasoned that the established system would be ideally suited to conduct direct in vivo RNAi screens for genes that positively or negatively impact the regenerative capacity of hepatocytes. The identification of such target genes holds the great promise of instructing new therapies to increase hepatocyte regeneration in diseased livers. Because it has been suggested that overlapping signaling pathways might control hepatocyte proliferation in liver regeneration and liver cancer (reviewed in Teoh, [2009] ), we decided to conduct a screen using a focused pool of 631 shRNAs targeting genes that were found embedded in focal genomic deletions of 100 human hepatocellular carcinomas (Zender et al., 2008) . The shRNA pool was subcloned into the p/T-FAHIG transposon vector (see Figure 1A ) and hydrodynamically codelivered with an SB13 transposase encoding vector into the livers of FAH À/À mice. To induce liver repopulation from hepatocytes with stable transposon integration, we took mice off NTBC. Under these conditions liver repopulation from hepatocytes with restored FAH expression is initiated and hepatocytes harboring shRNAs conferring a repopulation and regeneration advantage will outcompete those harboring neutral shRNAs or shRNAs whose knockdown even confers a disadvantage during liver repopulation ( Figure 2A ). The inflammatory reaction and cytokine milieu in FAH À/À livers after NTBC withdrawal reflects many features of chronically damaged, regenerating human livers (Grompe et al., 1995) , suggesting similar mechanisms of hepatocellular proliferation control in both settings. Nevertheless, as an additional model for liver regeneration under chronic damage, we also subjected mice, after successful liver repopulation with the shRNA library, to repetitive carbon tetrachloride (CCl 4 ) treatments (6 weeks), a well-defined and characterized model of chronic liver damage that shares many features of chronic liver disease in humans, including the development of liver fibrosis (Pierce et al., 1987) .
To quantify the abundance of each shRNA within the population, we isolated genomic DNA from individual livers after completion of liver repopulation and from livers after CCl 4 treatment (Figure 2A , n = 5 livers for each condition). shRNA cassettes were PCR amplified from genomic DNA as well as from the initial transposon shRNA pool and subjected to deep sequencing in order to quantify potential changes in the abundance of particular shRNAs during liver repopulation and CCl 4 -mediated chronic liver damage. Average values for shRNA representation in each of the three conditions were calculated and used to determine the x-fold shRNA enrichment or depletion comparing repopulated livers and CCl 4 -treated livers to the library pool (Figures 2B and 2C) . Expectedly, the majority of shRNAs had no impact on liver regeneration and therefore their frequency did not increase or decrease compared to the initial representation in the shRNA library pool ( Figures 2B and 2C ). However, we identified several shRNAs that were enriched during liver repopulation and also after CCl 4 treatment (Figures 2B and 2C). As a cutoff criterion for further studies, we chose to select shRNAs that were R 5-fold positively or negatively regulated in at least four out of five mice analyzed for each condition. Overall, out of 631 shRNAs that were screened, 11 shRNAs fulfilled these criteria in the repopulation group and 10 in the CCl 4 group ( Figures 2D and 2E ). Strikingly, in both groups we identified MKK4 as our top-scoring target, with an average shRNA enrichment of 3,900-fold in the repopulation group and 13,500-fold in the CCl 4 group. Because MKK4 is a kinase and should therefore represent a good drug target, we decided to follow up on this candidate gene.
RNAi-Mediated Suppression of MKK4 Expression Enhances the Regenerative Capacity of Hepatocytes
After confirmation of efficient MKK4 knockdown by two independent shRNAs ( Figures 3A and 3B ), we next sought to functionally validate MKK4 as a target gene to increase liver regeneration. For this purpose we developed an assay, wherein liver repopulation of FAH À/À livers occurs from limited amounts of primarily transfected hepatocytes ( Figure 3C ). We hypothesized that below a certain threshold of stably transfected FAH-expressing hepatocytes, liver repopulation would not be possible in the presence of a noncoding shRNA (shNC), whereas hepatocytes with RNAi-mediated MKK4 knockdown by virtue of their increased regenerative capacity should still be capable of regenerating the mouse liver ( Figure 3C ). Indeed, we found that already a 10-fold reduction of the amount of hydrodynamically delivered transposon DNA (2.5 mg) resulted in fatal liver failure due to insufficient liver repopulation ( Figures 3D and S3A ), when a nontargeting shRNA was delivered. In contrast, mice receiving transposable elements expressing MKK4-shRNAs with an equal primary transfection efficiency ( Figure S3B ) not only gained weight and successfully repopulated their livers under these conditions ( Figures 3D and S3A ), but even survived when the amount of primarily delivered transposon was reduced to onetwentieth ( Figures 3D and S3A ). In line with their survival and the detected gain in body weight over time, we found that mice having received MKK4-shRNA-encoding transposon already at day 20 after stable delivery showed 9.9% GFPpositive, repopulated liver surface, whereas at the same time point only 1.7% GFP-positive repopulated liver surface was found in livers that had received transposable elements encoding for a noncoding shRNA ( Figures 3E and 3F ). Because we did not detect differences in the number of apoptotic cells in repopulating shMKK4 livers compared to shNC livers ( Figure S3C ), our data suggest that the enhanced repopulation efficiency of hepatocytes with MKK4 knockdown in this model system is mainly due to enhanced hepatocyte proliferation.
MKK4 Knockdown Increases Hepatocyte Regeneration through Faster Cell-Cycle Entry and Progression
Partial hepatectomy is a well-established procedure to induce synchronized cell-cycle entry of all remaining hepatocytes after removal of two-thirds of the liver (Grisham, 1962) . In order to analyze the effect of MKK4 suppression on hepatocyte cell-cycle entry and progression in this model, we subjected mouse livers with stable intrahepatic expression of MKK4-shRNAs or noncoding shRNAs to partial hepatectomy (PH) and prepared nuclear extracts from the remaining and regenerating liver tissue at different time points after PH ( Figure 4A ). Strikingly, MKK4-shRNA-expressing livers showed a faster cell-cycle entry as indicated by cyclin E expression as early as 24 hr after PH, while in shNC-expressing livers cyclin E was detectable earliest, 38 hr after PH ( Figure 4B ). Cyclin A is required for cell-cycle progression through S phase and, indicative of a faster cell-cycle progression in shMKK4 livers, we found strong accumulation of cyclin A already 48 hr after PH (late S phase and G2 phase), while only weak cyclin A expression was detectable at 48 hr in shNC livers ( Figure 4B ). In line with these data, around twice as many Ki67-positive cells were detectable at 38 hr and 48 hr after PH in shMKK4 livers compared to shNC livers (Figures 4C and 4D) . Consistent with published data (Sakamoto et al., 1999) , we only detected a very low number of apoptotic cells in regenerating livers and no difference was detected between regenerating shMKK4 livers and shNC livers ( Figure S4A ). To address whether earlier cell-cycle entry and faster cell-cycle progression in shMKK4-expressing hepatocytes ultimately result in an increased number of shMKK4-expressing hepatocytes after PH, we codelivered an MKK4-shRNA or a noncoding shRNA together with GFP into wild-type mouse livers and subjected these livers to PH. Strikingly, when the number of GFP-positive hepatocytes was quantified 72 hr after hepatectomy, we detected nearly two-fold more GFP-positive hepatocytes in the shMKK4 transfected livers than in the shNC transfected livers Figure 1A ). Livers are efficiently repopulated from hepatocytes harboring stable transposon expression. A cohort of mice with fully repopulated mouse livers was subjected to CCl 4 treatment to induce chronic liver damage and liver regeneration. Hepatocytes with shRNAs whose knockdown confers an advantage will increase in number during liver regeneration and/or liver damage (indicated as black shRNAs) while those harboring disadvantageous shRNAs will deplete from the population (indicated by green shRNAs). The frequency of any shRNA in the population is quantified by deep sequencing. (B) Enrichment or depletion (log 2 scale) of a pool of 631 shRNAs that was screened as described in Figure 2A . The representation of each shRNA after repopulation of the liver (2 months after injection) was compared to its representation in the plasmid pool. Shown is the corrected mean fold change of five individually analyzed mice (blue bars). (C) Enrichment or depletion (log 2 scale) of 631 shRNAs that were screened as described in Fig Plotted is the x-fold change of shRNA abundance compared to the abundance of the respective shRNA in the library. (E) List of shRNAs that showed at least 5-fold change (positive or negative regulation) in four out of five analyzed animals after CCl 4 -mediated chronic liver damage. Plotted is the x-fold change of shRNA abundance compared to the abundance of the respective shRNA in the library.
( Figure S4B ), thus demonstrating that MKK4 knockdown results in an increased number of regenerated hepatocytes after partial hepatectomy.
MKK4 Knockdown Increases the Robustness of Hepatocytes In Vivo and In Vitro
Our data thus far showed increased hepatocyte proliferation and regeneration upon MKK4 knockdown in two mouse models of liver regeneration, the FAH À/À model of liver repopulation and the partial hepatectomy model. To ultimately probe the potential of MKK4 inhibition as a strategy to increase liver regeneration in liver disease, we next subjected mice with stable intrahepatic expression of MKK4-or noncoding shRNAs to a treatment with CD95 (FAS)-activating antibodies ( Figure 5A ), a well-established mouse model of acute liver failure (ALF) (Ogasawara et al., 1993) . Interestingly, MKK4 silencing not only increased compensatory hepatocyte proliferation in this setting (data not shown) but also enhanced the robustness of hepatocytes, as reflected by a significantly decreased number of apoptotic hepatocytes upon the induction of liver failure ( Figures 5B and 5C ). Importantly, decreased numbers of apoptotic cells in MKK4-shRNAexpressing livers resulted in an increased long-term survival of mice after induction of liver failure ( Figure 5D ). Over the past couple of years strategies to isolate and transplant human hepatocytes into diseased livers have been advanced and already entered the clinic (Chistiakov, 2012) . Because our data showed that MKK4 suppression may also increase the robustness of hepatocytes, we next wanted to explore whether MKK4 inhibition may represent a strategy to increase the efficiency of hepatocyte culture, transplantation, and engraftment. Primary hepatocytes were isolated from mouse livers stably expressing either MKK4-shRNAs or noncoding shRNAs and taken into primary culture. Compared to shNCexpressing hepatocytes, we found that shMKK4-expressing hepatocytes showed increased survival in culture and, even after prolonged in vitro culture, could be replated ( Figure 5E ) or transplanted into FAH À/À mice, where they efficiently repopulated the liver ( Figure 5F ). Therefore, MKK4 may also represent a ShMKK4 mediates a strong survival advantage (n = 5 per group). Statistical significance was calculated using the log rank test.
(E) GFP imaging of explanted mouse livers reveals enhanced clonal expansion (repopulation) of hepatocytes stably expressing shMKK4 compared to hepatocytes expressing shNC (day 20 after injection of 2.5 mg of the indicated plasmid). Two representative photographs are shown for each group (n = 5). (F) Quantification of GFP-positive liver surface (corresponding to E) by GSA-ImageAnalyser reveals a significanty higher GFP-positive liver surface in livers of p/T-FAHIG-shMKK4-injected mice compared to the control (data are presented as mean ± SEM). Statistical significance was calculated using Student's t test. See also Figure S3 . promising target to improve hepatocyte transplantation or to increase survival of primary human hepatocytes-for example, within bioartificial liver devices.
Because increased proliferation and apoptosis resistance are also hallmarks of malignant growth, we next sought to address the risk of promoting tumorigenesis by MKK4 suppression. Mice with stable intrahepatic MKK4 knockdown were monitored for liver tumor development for 12 months; however, none of the mice developed GFP-positive, shMKK4-expressing tumors (Figures S5A and S5B ). In line with published reports on the FAH À/À model (Grompe et al., 1995) , only few GFP-negative background tumors arose independently of the expressed shRNA (Figure S5B) . Nevertheless, to further characterize potential protumorigenic effects upon MKK4 inhibition, we analyzed the tumorigenicity of a nontumorigenic hepatocyte cell line (AML12) and immortalized liver progenitor cells (BNL CL.2 cells) after RNAi-mediated MKK4 knockdown. However, while in both cell lines RNAi-mediated knockdown of the well-established PTEN tumor suppressor and subsequent subcutaneous cell transplantation on nude mice readily induced oncogenic transformation and tumor growth, no tumor growth was observed when MKK4 was inhibited ( Figures S5C and S5D ). We also found that PTEN knockdown strongly accelerated tumor growth when fully transformed, tumorigenic BNL 1NG A.2 cells were transplanted on nude mice; however, compared to shNC-expressing cells, there was no acceleration of tumor growth when MKK4 was silenced ( Figure S5E ). Taken together, our data suggest that suppression of MKK4 is neither likely to be a strong tumor initiator nor likely to be a strong tumor accelerator; however, our current data cannot exclude the possibility that long-term MKK4 suppression may promote tumorigenesis in some settings.
MKK4 Suppression in Hepatocytes Reduces Fibrosis Development during Chronic Liver Damage
Chronic liver failure due to chronic hepatitis B or C virus infection or alcohol abuse represents a major health problem with about one million deaths per year (World Health Organization, 2011). Chronic liver damage results in repetitive waves of hepatocyte death and regeneration and ultimately, after the regenerative capacity of hepatocytes is exhausted, leads to the development of liver fibrosis and liver failure (Hernandez-Gea and Friedman, 2011; Kisseleva and Brenner, 2011) . In addition to the tested mouse models of liver repopulation, liver regeneration, and acute liver failure, we therefore wanted to investigate whether suppression of MKK4 also increases liver regeneration during chronic liver damage and thus may represent a therapeutic strategy in chronic liver disease. Mice with stable intrahepatic expression of MKK4-shRNAs or noncoding shRNAs were subjected to long-term treatment with carbon tetrachloride (CCl 4 ) ( Figure 6A ), a widely used model for chronic liver damage and the development of liver fibrosis (Pierce et al., 1987) . Strikingly, MKK4 silencing led to a significant reduction of fibrosis development ( Figures 6B-6E actin staining and hydroxyproline ELISA. Mechanistically, we found significantly more proliferating hepatocytes in chronically damaged, regenerating shMKK4-expressing mouse livers (Figures 6F and 6G) . Interestingly, TUNEL staining also revealed that mouse livers with reduced MKK4 suppression showed an increased protection against apoptosis ( Figures 6H and 6I ), thus suggesting that both increased hepatocyte proliferation and decreased hepatocyte death may confine fibrosis development in shMKK4-expressing livers.
MKK4 Suppression Increases Hepatocyte Regeneration via Compensatory Upregulation of MKK7 and a JNK1-Dependent Activation of ATF2 and ELK1
We were interested in exploring the molecular mechanism whereby MKK4 knockdown increases the regenerative capacity of hepatocytes. MKK4 is a dual-specific protein kinase that is embedded in both major stress-kinase signaling pathways, the p38 and the JNK pathway (Davis, 2000; Lee et al., 2002) , and it has been reported that p38 and JNK signaling act antagonistically on hepatocyte proliferation and liver regeneration (Wada et al., 2008) , whereas JNK signaling is believed to be proliferative and p38 signaling antiproliferative. Recent data suggested that JNK activation depends on activating signals from both upstream kinases, MKK4 and MKK7; however, despite highly efficient MKK4 knockdown ( Figures 3A and 3B ), we found a strong increase of p-JNK levels in shMKK4-expressing mouse livers by phoshoprotein antibody array profiling and western blotting ( Figures 7A and 7C ). In support of the idea that robust MKK7 expression levels alone may be sufficient to induce p-JNK, we detected a strong induction of ASK-1, an (E) Phase-contrast microscopy of primary hepatocyte cultures reveals increased long-term survival of isolated primary hepatocytes expressing shMKK4 (left upper panel, d29 after plating) compared to shNC-expressing hepatocytes (left lower panel, d12 after plating). Hepatocytes expressing shMKK4 can be efficiently replated after trypsinization (shown is day 3 after replating, = d15 after initial plating). Experiments were done in triplicates (isolation from independently repopulated mice). Shown are representative photographs (100 3 magnification). (F) Efficient liver repopulation and survival after transplantation of shMKK4-expressing hepatocytes (kept 7 days in culture) into FAH À/À mice.
Shown is a Kaplan Meier survival analysis of mice after intrahepatic seeding of shMKK4 or shNC-expressing hepatocytes (500,000 hepatocytes transplanted, n = 6 per group). Statistical significance was calculated using a log rank test. See also Figure S5 .
upstream kinase that can activate MKK7, as well as induction of MKK7 itself ( Figures 7A and 7B ). In line with the idea that MKK4 suppression may alter the balance between p38 and JNK signaling, we found decreased expression of p-p38 and its downstream target p-HSP27 ( Figures 7A, 7D , and 7E). However, the AP1 transcription factor c-Jun, a classical downstream target of JNK, was not found induced but rather decreased in shMKK4-expressing livers ( Figure 7F ), thus suggesting that MKK4 inhibition results in a more complex downstream signature of p38 and JNK target genes that probably also involves altered cross-signaling between both pathways. As p-c-Jun levels were decreased in mouse livers with stable MKK4 knockdown, it is likely that other JNK downstream mediators may convey the proregenerative signals in mouse livers with stable MKK4 suppression. As possible candidates, we identified the AP1 transcription factor ATF2 ( Figures 7A and 7G) and the E twenty-six (Ets) factor Elk1 ( Figure 7A ) as upregulated in shMKK4-expressing livers.
To functionally probe which of the identified factors are crucial for increased hepatocyte regeneration upon MKK4 inhibition, we developed a unique transposon vector that allows for an efficient coexpression of two shRNAs ( Figures 7H and 7I) . Efficient shRNAs targeting MKK7, JNK1 (MAPK8), JNK2 (MAPK9), ATF2, and ELK1 were generated ( Figures S6A-S6E ) and codelivered individually with an MKK4-shRNA into FAH À/À mouse livers.
For the experiment, we stably transfected 1.25 mg of transposon DNA, an amount that only allows liver repopulation from hepatocytes harboring MKK4 knockdown ( Figures 3D and S3A) . Codelivery of an MKK4-shRNA together with a noncoding shRNA (shNC) served as a control. NTBC was withdrawn to induce liver repopulation and mice were harvested 15 days after NTBC withdrawal to quantify the number of GFP-positive Statistical significance was calculated using Student's t test.
liver-repopulating hepatocyte clones ( Figures 7J-7O and S6F-S6J). We found efficient liver repopulation when shMKK4 was codelivered with a noncoding shRNA with more than 300 macroscopically visible GFP-positive clones already being visible at this time point. In strong contrast, liver repopulation was significantly reduced (only 20 GFP-positive clones) when shMKK4 was codelivered with an shRNA-targeting MKK7, which we had found to be compensatorily upregulated in hepatocytes with MKK4 knockdown ( Figure 7B ). MKK7 is known to signal to JNK1 as well as JNK2; however, we found that only JNK1 inhibition, but not JNK2 inhibition, abolishes the proregenerative effects of MKK4 knockdown, whereas JNK2 silencing was able to even further enhance regeneration upon MKK4 silencing ( Figures 7J, 7L , 7M, and S6G-S6H). Interestingly, RNAi-mediated knockdown of two independent downstream factors of JNK1, the AP1 factor ATF2 and the Ets factor ELK1, each greatly decrease the regenerative capacity of MKK4 knockdown hepatocytes ( Figures 7N  and 7O ). In further support of a crucial role of ELK1 in liver regeneration, we found that ELK1 knockout mice (Cesari et al., 2004) show a markedly reduced hepatocyte proliferation upon partial hepatectomy ( Figure S7) .
Overall, our functional genetic data show that induction of MKK7 and a JNK1-dependent activation of the AP1 transcription factor ATF2 and the Ets factor ELK-1 are crucial for the increased regenerative capacity of hepatocytes upon MKK4 inhibition.
DISCUSSION
This study describes a direct in vivo RNAi screen for gene targets that can be exploited to increase the endogenous regenerative capacity of hepatocytes. In contrast to other in vivo RNAi screens that rely on the ex vivo transduction of target cells with shRNA pools and subsequent transplantation of these cells into mice (Zender et al., 2008; Zuber et al., 2011) , this system permits direct in vivo screening, and target cells for shRNA expression are never taken out of their natural tissue microenvironment. Besides future use for genome-wide shRNA screens, it is also suited for individually analyzing candidate genes, because mice with stable and liver-specific knockdown phenotypes for any desired target gene can be generated within 2 months.
We identify the dual-specific kinase MKK4 as a master regulator of liver regeneration. MKK4 represents a dual-specific protein kinase that is essential for liver organogenesis (Ganiatsas et al., 1998) . Embryonic mouse livers of MKK4 knockout mice contain high numbers of highly proliferating embryonic hepatocytes (hepatoblasts) but die because these cells cannot differentiate into hepatocytes (Ganiatsas et al., 1998) . We show that MKK4 inhibition in adult hepatocytes greatly enhances their proliferative and regenerative potential, but notably, and in contrast to embryonic livers, the regeneration process stops after liver repopulation has been completed. Therefore, signaling pathways controlling proliferation and growth during embryonic development may be revisited for the development of strategies to induce or increase endogenous regeneration in adult somatic tissues.
Despite the fact that hepatocytes harbor a nearly infinite capacity to proliferate under physiological conditions (Overturf et al., 1997a) , liver regeneration defects are often encountered in chronic liver diseases. MKK4 inhibition could mobilize regenerative reserves of hepatocytes under liver damage and showed robust therapeutic efficacy in mouse models of acute and chronic liver failure. Interestingly, MKK4 silencing resulted in reduced fibrosis development in the carbon tetrachloride (CCl 4 ) model, a well-established mouse model for chronic liver damage and fibrosis induction (Pierce et al., 1987) . Liver fibrogenesis is mediated by a heterogenous population of profibrogenic myofibroblasts, the majority originating from hepatic stellate cells, and it was shown that the activation of hepatic stellate cells represents a critical event in fibrosis, because these cells become the primary source of extracellular matrix in injured livers (Hernandez-Gea and Friedman, 2011) . While current therapeutic strategies to curtail fibrosis and cirrhosis development and progression mainly focus on targeting profibrogenic cytokines and nonparenchymal liver cells such as activated myofibroblasts (Kisseleva and Brenner, 2011) , our data suggest that hepatocyte-intrinsic gene targets may also be exploited to confine fibrosis development.
We found that MKK4 inhibition results in a faster cell-cycle entry and progression of hepatocytes during liver regeneration. Different phases of liver regeneration have been defined and the priming phase describes a critical and rate-limiting step during liver regeneration, where hepatocytes in responses to extrinsic stimuli leave the G 0 phase and enter the G 1 phase of the cell cycle (Taub, 2004) . Against the background of the identified accelerated cell-cycle entry our data support a model where MKK4 inhibition may render hepatocytes more sensitive to external priming phase-inducing stimuli, or it may even be speculated that hepatocytes with MKK4 knockdown reside in a ''permanent priming phase'' and can therefore quickly enter the cell cycle and give rise to new hepatocytes.
Interestingly, it was recently shown that regenerating livers are protected against Fas-induced apoptosis (Desbarats and Newell, 2000) . Our data show that resting, nonregenerating livers with MKK4 silencing already show increased resistance against Fas-induced apoptosis, suggesting that a constitutive priming phase might mediate the increased robustness.
Increased proliferation and apoptosis resistance are hallmarks of malignant cell growth. We followed mice with stable intrahepatic knockdown for 12 months, to monitor any tumor development; however, no tumors with MKK4-shRNA expression were observed during this period, suggesting that loss of MKK4 is unlikely to be a strong tumor-initiating event. Furthermore, classical tumorigenicity assays revealed that MKK4 knockdown was neither able to malignantly transform nontumorigenic murine liver cells, nor able to accelerate tumor growth of readily transformed murine liver carcinoma cells. Nevertheless, our data do not exclude the possibility that reduced MKK4 expression or impaired MKK4 function due to mutations may contribute to tumor progression in some settings. Our screen was based on the assumption that proliferation control during tissue regeneration and tumorigenesis depend on overlapping signaling pathways and the screened shRNA library contained shRNAs against gene targets that were found embedded in focal genomic deletions in human hepatocellular carcinoma (Zender et al., 2008) . In our data set of 100 human hepatocellular carcinomas analyzed by high-resolution array-based comparative genomic hybridization, we found one tumor with a focal genomic deletion encompassing MKK4 (Zender et al., 2008) . Also, MKK4 has been discussed as a tumor suppressor gene in ovarian and lung cancer (Yeasmin et al., 2011; Ahn et al., 2011) . While collectively these data suggest that MKK4 suppression or altered function may contribute to tumor progression in some settings, we believe that a therapeutic window for transient and intermittent pharmacological MKK4 inhibition to increase liver regeneration exists.
The only curative and definitive treatment option for fulminant acute liver failure and end-stage chronic liver failure is liver transplantation; however, the number of available donor livers is limited. Our data show that MKK4 inhibition increases the regenerative capacity of hepatocytes in settings of acute and chronic liver damage, and pharmacological MKK4 inhibitors may therefore represent a strategy for the treatment of patients with acute or chronic liver disease.
Taken together, the herein outlined strategies describe an approach to discover gene targets that can be exploited to increase the regenerative capacity of hepatocytes. Against the background of our current knowledge of signaling pathways that control hepatocyte proliferation, a hypothesis-driven selection of MKK4 as a potential target to increase liver regeneration would have been unlikely. We therefore believe that our study once more emphasizes the power of unbiased functional genetic screens to identify new gene targets in different biological systems. Specifically, our study serves as a blueprint for how RNAi-based functional genetic screens can be used to identify gene targets to increase the endogenous regenerative capacity of tissues.
EXPERIMENTAL PROCEDURES
Mice and Hydrodynamic Injection FAH knockout mice have been generated by Dr. Markus Grompe (Grompe et al., 1995) (Oregon Health Sciences University) and were obtained in a C57BL/6 background from Dr. Arndt Vogel (Hannover Medical School). Mice were kept on the drug NTBC (2-[2-nitro-4-{trifluoromethyl}benzoyl]cyclohexane-1,3-dione) at 19.2 mg per 1 liter drinking water to prevent liver failure. NMRI nu/nu mice for subcutaneous tumor studies were purchased from Harlan laboratories (Rossdorf, Germany). ELK knockout mice were generated and kindly provided by Dr. Alfred Nordheim (Cesari et al., 2004) . All mice were maintained under pathogen-free conditions in accordance with the institutional guidelines of the Helmholtz Centre for Infection Research and Hannover Medical School. All animal experiments have been approved by the German legal authorities.
Vectors for hydrodynamic tail vein injection were prepared using the QIAGEN EndoFree Maxi Kit (QIAGEN). For transposon-mediated gene transfer, animals received a 5:1 molar ratio of transposon to transposase-encoding plasmid (25 mg total DNA, unless otherwise stated). DNA was suspended in saline solution at a final volume of 10% of the animal's body weight and injected via the tail vein in less than 10 s. For transient, intrahepatic expression of luciferase, 5 mg of pcDNA-Luc or the pBlueSK control vector was delivered intrahepatically by hydrodynamic tail vein injection. Progression of liver repopulation was monitored at different time points by whole-liver GFP imaging using a Hamamatsu Imaging system. The GFP-positive liver surface area was calculated using the software GSA-ImageAnalyser (GSA). Whole-body bioluminescence imaging was done as described before (Xue et al., 2007) . Luciferase imaging was done in living mice using the IVIS in vivo imaging system (Xenogen). Mice were intraperitoneally injected with D-luciferin (SynchemOHG) (7.5 mg/g body weight), anesthetized with Isoflurane (Albrecht), and analyzed 10 min after injection.
Two-Thirds Hepatectomy
Two-thirds (partial) hepatectomy was performed on repopulated FAH À/À mice as described before (Mitchell and Willenbring, 2008) . The median, right, and caudate liver lobes were surgically removed while mice were under general anesthesia.
Carbon Tetrachloride (CCl 4 ) Treatment CCl 4 treatment was performed for a 6 week period by intraperitoneal injection twice per week. The mice received 0.25 ml/kg body weight CCl 4 (Sigma) dissolved in sunflower oil (Sigma).
A detailed description of all experimental procedures is provided in the Extended Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures and seven figures and can be found with this article online at http://dx.doi.org/ 10.1016/j.cell.2013.03.026.
